Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Eli Lilly stock fell sharply after the drug maker posted quarterly earnings that missed analysts’ expectations. The company reported adjusted earnings of $1.18 a share on revenue of $11.44 billion, compared to analysts’ estimates for earnings of $1.